Permitting Product Liability Litigation for FDA‐Approved Drugs and Devices Promotes Patient Safety

In 2008 and 2009, the Supreme Court reviewed the question of whether patients injured by dangerous prescription drugs or medical devices can bring tort lawsuits against pharmaceutical and device manufacturers. The Court ruled that claims against device manufacturers were preempted while claims against pharmaceutical manufacturers were not. The threat of product liability lawsuits promotes patient safety by encouraging manufacturers to take greater responsibility in providing clear warnings about known adverse effects of their products.

[1]  D. Vladeck A Critical Examination of the FDA's Efforts to Preempt Failure-to-Warn Claims , 2007 .

[2]  Stephen B. Johnson,et al.  Central challenges facing the national clinical research enterprise. , 2003, JAMA.

[3]  DE Mager,et al.  Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.

[4]  S. Albani,et al.  The advancement of translational medicine—from regional challenges to global solutions , 2009, Nature Medicine.

[5]  W. Maisel,et al.  Semper fidelis--consumer protection for patients with implanted medical devices. , 2008, The New England journal of medicine.

[6]  D. Stoff,et al.  Moving toward paradigm-shifting research in health disparities through translational, transformational, and transdisciplinary approaches. , 2010, American journal of public health.

[7]  M. Piquette-Miller,et al.  Translational Pharmacology: Harnessing Increased Specialization of Research Within the Basic Biological Sciences , 2008, Clinical pharmacology and therapeutics.

[8]  D. Abernethy,et al.  Finding the Right Research Question: Quality Science Depends on Quality Careers , 2008, Clinical pharmacology and therapeutics.

[9]  J. Wyngaarden The president's address. "The clinical investigator as an endangered species". , 1979, Transactions of the Association of American Physicians.

[10]  Aaron S Kesselheim,et al.  The role of litigation in defining drug risks. , 2007, JAMA.

[11]  Y. Aulchenko,et al.  A powerful genome-wide feasible approach to detect parent-of-origin effects in studies of quantitative traits , 2010, European Journal of Human Genetics.